白细胞分化抗原36与2型糖尿病相关性的研究进展

黄倩; 刘德亮; 李惠林

doi:10.16766/j.cnki.issn.1674-4152.003085

白细胞分化抗原36与2型糖尿病相关性的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.003085

黄倩^{1, 2},
刘德亮²,
李惠林^2, ,

1.
广州中医药大学第四临床医学院，广东深圳 518033
2.
深圳市中医院内分泌科，广东深圳 518033

基金项目:

国家自然科学基金项目 81774225

国家自然科学基金项目 81704002

广东省基础与应用基础研究基金项目 2020A1515010775

详细信息

通讯作者:
李惠林，E-mail: sztcmlhl@163.com

中图分类号: R587.1
计量
- 文章访问数: 152
- HTML全文浏览量: 39
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-11
- 网络出版日期: 2023-08-28

Research progress on correlations between CD36 and type 2 diabetes mellitus

HUANG Qian^{1, 2},
LIU Deliang²,
LI Huilin^{2
, ,}

1.
The Fourth Clinical Medicine College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518033, China

摘要

摘要: 随着全球经济的飞速发展、人民生活水平的提高及生活方式的改变，糖尿病已成为威胁全人类生命健康的重要非传染性疾病之一，其中，2型糖尿病(T2DM)是其主要类型。目前虽然已有许多针对T2DM不同靶点的药物，但其疗效不尽如人意，且可能伴随如腹胀、恶心呕吐、体重增加、泌尿道感染等副作用。因此，寻找新的药物治疗靶点，开发新的治疗药物迫在眉睫且意义重大。胰岛素抵抗(IR)和(或)胰岛素分泌缺陷是T2DM发生、发展的重要环节，因此，寻找新的途径改善IR及调控胰岛β细胞胰岛素分泌是T2DM治疗的关键手段和重要方向。白细胞分化抗原36(CD36)是一种多功能膜蛋白受体，在机体多种细胞广泛表达，其能通过识别并结合不同的配体参与调节糖脂代谢、粘附、凋亡、炎症反应及免疫应答等多种生理和病理过程，从而参与T2DM的发生与进展。糖尿病环境下，机体主要胰岛素靶组织(包括肝脏、脂肪、骨骼肌)上高表达的CD36通过多种机制参与IR的进程，CD36还通过介导氧化应激、内质网应激、炎症反应等多种病理过程参与胰岛β细胞的分泌和死亡。此外，CD36还能通过介导脂肪感知信号传导调节脂肪偏好及摄食行为，进而参与T2DM的发生及进展过程。因此，通过调控CD36在各个组织器官的表达水平来治疗T2DM有可能成为未来治疗T2DM及相关代谢性疾病的重要途径。
- 2型糖尿病 /
- 白细胞分化抗原36 /
- 胰岛素抵抗
Abstract: With the rapid development of the global economy, the improvement of people's living standards and the changes of their life style, diabetes has become one of the most severe noncommunicable diseases threatening the life and health of the whole of humanity, among which type 2 diabetes mellitus (T2DM) accounts for the vast majority of cases. Although there are many kinds of drugs targeting different targets of T2DM, their efficacy is not satisfactory, and may be accompanied by some side-effects, such as abdominal bloating, nausea and vomiting, weight gain, urinary tract infection and so on. Therefore, it is urgent and significant to find new therapeutic targets and develop new therapeutic drugs for T2DM. T2DM is primarily caused by insufficient insulin secretion by the pancreatic β cells and/or insulin resistance (IR) in peripheral tissues. Thus, it is important to find new ways to improve IR and regulate insulin secretion of pancreatic β cells for the treatment of T2DM. Cluster of differentiation 36 (CD36) is a multifunctional membrane protein receptor, which is widely expressed in various cells of the body. It participates in the occurrence and progression of T2DM through recognizing and binding different ligands to regulate lipid metabolism, adhesion, apoptosis, inflammatory response and immune response and other physiological and pathological processes. An increased expression of CD36 induced by hyperglycemia in the main insulin target tissues, including liver, fat and skeletal muscle, is involved in IR through various mechanisms. In addition, CD36 also participates in the process of insulin secretion and pancreatic β cell death by mediating oxidative stress, endoplasmic reticulum stress, inflammation and other pathological processes. Furthermore, CD36 also regulates fat preference and feeding behavior by mediating fat perception signal transduction, participating in the occurrence and progression of T2DM. Therefore, regulation of the expression level of CD36 in various tissues and organs may become an important approach for the treatment of T2DM and related metabolic diseases in the future.
- Type 2 diabetes mellitus /
- Cluster of differentiation 36 /
- Insulin resistance

HTML全文

参考文献(43)

[1]	BALLAN R, SAAD S M I. Characteristics of the gut microbiota and potential effects of probiotic supplements in individuals with type 2 diabetes mellitus[J]. Foods, 2021, 10(11): 2528. doi: 10.3390/foods10112528
[2]	SUN H, SAEEDI P, KARURANGA S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[3]	LE TORIELLEC E, MURALITHARAN V, CHADEBECH P, et al. New molecular basis associated with CD36-negative phenotype in the sub-Saharan African population[J]. Transfusion, 2020, 60(11): 2482-2488. doi: 10.1111/trf.15980
[4]	SHU H, PENG Y, HANG W, et al. The role of CD36 in cardiovascular disease[J]. Cardiovasc Res, 2022, 118(1): 115-129. doi: 10.1093/cvr/cvaa319
[5]	ABDULAMEER Q A, AZIZ I H, ABDULHASSAN I A, et al. The effect of genetic variation of CD36 gene on sample of Iraqi patients with essential hypertension[J]. Iraqi J Biotechnol, 2021, 1(20): 1-6.
[6]	ZHAO L, VARGHESE Z, MOORHEAD J F, et al. CD36 and lipid metabolism in the evolution of atherosclerosis[J]. Br Med Bull, 2018, 126(1): 101-112. doi: 10.1093/bmb/ldy006
[7]	FAN C, LIANG W, WEI M, et al. Effects of D-Chiro-Inositol on glucose metabolism in db/db mice and the associated underlying mechanisms[J]. Front Pharmacol, 2020, 11: 354. doi: 10.3389/fphar.2020.00354
[8]	JAMES D E, STÖCKLI J, BIRNBAUM M J. The aetiology and molecular landscape of insulin resistance[J]. Nat Rev Mol Cell Biol, 2021, 22(11): 751-771. doi: 10.1038/s41580-021-00390-6
[9]	AHMED B, SULTANA R, GREENE M W. Adipose tissue and insulin resistance in obese[J]. Biomed Pharmacother, 2021, 137: 111315. DOI: 10.1016/j.biopha.2021.111315.
[10]	GLATZ J, LUIKEN J. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization[J]. J Lipid Res, 2018, 59(7): 1084-1093. doi: 10.1194/jlr.R082933
[11]	罗小青, 曾晗, 谭伟, 等. CD36基因缺失改善高脂饮食诱导的糖代谢异常并促进肝脏脂质积聚[J]. 生理学报, 2021, 73(5): 805-812. doi: 10.13294/j.aps.2021.0021 LUO X Q, ZENG H, TAN W, et al. Deletion of CD36 gene ameliorates glucose metabolism abnormality induced by high-fat diet and promotes liver lipid accumulation[J]. Acta Physiologica Sinica, 2021, 73(5): 805-812. doi: 10.13294/j.aps.2021.0021
[12]	WILSON C G, TRAN J L, ERION D M, et al. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice[J]. Endocrinology, 2016, 157(2): 570-585. doi: 10.1210/en.2015-1866
[13]	STENEBERG P, SYKARAS A G, BACKLUND F, et al. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter CD36 and provokes hepatosteatosis and hepatic insulin resistance[J]. J Biol Chem, 2015, 290(31): 19034-19043. doi: 10.1074/jbc.M115.640292
[14]	LI Y, YANG P, ZHAO L, et al. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway[J]. J Lipid Res, 2019, 60(4): 844-855. doi: 10.1194/jlr.M090969
[15]	GARBACZ W G, LU P, MILLER T M, et al. Hepatic overexpression of CD36 improves glycogen homeostasis and attenuates high-fat diet-induced hepatic steatosis and insulin resistance[J]. Mol Cell Biol, 2016, 36(21): 2715-2727. doi: 10.1128/MCB.00138-16
[16]	YANG P, ZENG H, TAN W, et al. Loss of CD36 impairs hepatic insulin signaling by enhancing the interaction of PTP1B with IR[J]. FASEB J, 2020, 34(4): 5658-5672. doi: 10.1096/fj.201902777RR
[17]	DAQUINAG A C, GAO Z, FUSSELL C, et al. Fatty acid mobilization from adipose tissue is mediated by CD36 posttranslational modifications and intracellular trafficking[J]. JCI Insight, 2021, 6(17): e147057. DOI: 10.1172/jci.insight.147057.
[18]	CYR Y, BISSONNETTE S, LAMANTIA V, et al. White adipose tissue surface expression of LDLR and CD36 is associated with risk factors for type 2 diabetes in adults with obesity[J]. Obesity, 2020, 28(12): 2357-2367. doi: 10.1002/oby.22985
[19]	FERNANDES-DA-SILVA A, MIRANDA C S, SANTANA-OLIVEIRA D A, et al. Endoplasmic reticulum stress as the basis of obesity and metabolic diseases: focus on adipose tissue, liver, and pancreas[J]. Eur J Nutr, 2021, 60(6): 2949-2960. doi: 10.1007/s00394-021-02542-y
[20]	KARUNAKARAN U, ELUMALAI S, MOON J, et al. CD36 Signal transduction in metabolic diseases: novel insights and therapeutic targeting[J]. Cells, 2021, 10(7): 1833. doi: 10.3390/cells10071833
[21]	ZHAO J, RUI H, YANG M, et al. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy[J]. Mediators Inflamm, 2019, 2019: 1-16. DOI: 10.1155/2019/3172647.
[22]	JESUS J D C R, MURARI A S D P, RADLOFF K, et al. Activation of the adipose tissue NLRP3 inflammasome pathway in cancer cachexia[J]. Front Immunol, 2021, 12: 729182. DOI: 10.3389/fimmu.2021.729182.
[23]	MENTESE A, DOGRAMACI S, DEMIR S, et al. The effect of homocysteine on the expression of CD36, PPARγ, and C/EBPα in adipose tissue of normal and obese mice[J]. Arch Physiol Biochem, 2021, 127(5): 437-444. doi: 10.1080/13813455.2019.1648517
[24]	LIU M, TSO P, WOODS S C. Receptor CD36 links a risk-associated allele to obesity and metabolic disorders[J]. J Biol Chem, 2018, 293(34): 13349-13350. doi: 10.1074/jbc.H118.004818
[25]	LUO X, LI Y, YANG P, et al. Obesity induces preadipocyte CD36 expression promoting inflammation via the disruption of lysosomal calcium homeostasis and lysosome function[J]. Ebiomedicine, 2020, 56: 102797. DOI: 10.1016/j.ebiom.2020.102797.
[26]	MENGESTE A M, RUSTAN A C, LUND J. Skeletal muscle energy metabolism in obesity[J]. Obesity, 2021, 29(10): 1582-1595. doi: 10.1002/oby.23227
[27]	GILBERT M. Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes[J]. J Diabetes Investig, 2021, 12(11): 1934-1941. doi: 10.1111/jdi.13614
[28]	VERPOORTEN S, SFYRI P, SCULLY D, et al. Loss of CD36 protects against diet-induced obesity but results in impaired muscle stem cell function, delayed muscle regeneration and hepatic steatosis[J]. Acta Physiol, 2019, 228(3): e13395. DOI: 10.1111/apha.13395.
[29]	SAMOVSKI D, SUN J, PIETKA T, et al. Regulation of AMPK activation by CD36 links fatty acid uptake to β-oxidation[J]. Diabetes, 2015, 64(2): 353-359. doi: 10.2337/db14-0582
[30]	GLATZ J C, LUIKEN J F P. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization[J]. J Lipid Res, 2018, 59(7): 1084-1093. doi: 10.1194/jlr.R082933
[31]	MAUNDER E, PLEWS D J, WALLIS G A, et al. Peak fat oxidation is positively associated with vastus lateralis CD36 content, fed-state exercise fat oxidation, and endurance performance in trained males[J]. Eur J Appl Physiol, 2022, 122(1): 93-102. doi: 10.1007/s00421-021-04820-3
[32]	SHOU J, CHEN P, XIAO W. Mechanism of increased risk of insulin resistance in aging skeletal muscle[J]. Diabetol Metab Syndr, 2020, 12(1): 1-10. doi: 10.1186/s13098-019-0485-z
[33]	孙婧瑜, 苏亚娟, 秦黎黎, 等. FAT/CD36表达及转位在有氧运动改善老年小鼠骨骼肌胰岛素敏感性中的作用[J]. 中国体育科技, 2021, 57(2): 3-11. doi: 10.16470/j.csst.2019124 SUN J Y, SU Y J, QIN L L, et al. Aerobic exercise improves aging induced skeletal muscle insulin sensitivity through FAT/CD36 expression and translocation[J]. China Sport Science and Technology, 2021, 57(2): 3-11. doi: 10.16470/j.csst.2019124
[34]	MOON J S, KARUNAKARAN U, ELUMALAI S, et al. Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells[J]. J Diabetes Complications, 2017, 31(1): 21-30. doi: 10.1016/j.jdiacomp.2016.09.001
[35]	KARUNAKARAN U, ELUMALAI S, MOON J S, et al. CD36 dependent redoxosomes promotes ceramide-mediated pancreatic β-cell failure via p66Shc activation[J]. Free Radic Biol Med, 2019, 134: 505-515. doi: 10.1016/j.freeradbiomed.2019.02.004
[36]	NAGAO M, ESGUERRA J, ASAI A, et al. Potential protection against type 2 diabetes in obesity through lower CD36 expression and improved exocytosis in β-cells[J]. Diabetes, 2020, 69(6): 1193-1205. doi: 10.2337/db19-0944
[37]	TENG W, LI Y, DU M, et al. Sulforaphane prevents hepatic insulin resistance by blocking serine palmitoyltransferase 3-mediated ceramide biosynthesis[J]. Nutrients, 2019, 11(5): 1185. doi: 10.3390/nu11051185
[38]	HANDBERG A, LEVIN K, HØJLUND K, et al. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance[J]. Circulation, 2006, 114(11): 1169-1176. doi: 10.1161/CIRCULATIONAHA.106.626135
[39]	HANDBERG A, NORBERG M, STENLUND H, et al. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk[J]. J Clin Endocrinol Metab, 2010, 95(4): 1939-1946. doi: 10.1210/jc.2009-2002
[40]	KIM H J, MOON J S, PARK I R, et al. A novel index using soluble CD36 is associated with the prevalence of type 2 diabetes mellitus: comparison study with triglyceride-glucose index[J]. Endocrinol Metab, 2017, 32(3): 375-382. doi: 10.3803/EnM.2017.32.3.375
[41]	CASTELBLANCO E, SANJURJO L, FALGUERA M, et al. Circulating soluble CD36 is similar in type 1 and type 2 diabetes mellitus versus non-diabetic subjects[J]. J Clin Med, 2019, 8(5): 710. doi: 10.3390/jcm8050710
[42]	王声翰, 杨菊红, 郑妙艳, 等. 可溶性CD36与2型糖尿病及其并发症的关系[J]. 中华全科医学, 2020, 18(11): 1921-1924. doi: 10.16766/j.cnki.issn.1674-4152.001654 WANG S H, YANG J H, ZHENG M Y, et al. Association of soluble CD36 with type 2 diabetes and its complications[J]. Chinese Journal of General Practice, 2020, 18(11): 1921-1924. doi: 10.16766/j.cnki.issn.1674-4152.001654
[43]	曾子文. 基于"舌-心(神)-欲"探讨不同糖代谢状态下的脂肪偏好及敏感性[D]. 广州: 广州中医药大学, 2020. ZENG Z W. To explore the fat preference and sensitivity under different glucose metabolism states based on "tongue, heart (spirit) and desire"[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2020.